Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

08/02/2019 Barcelona Synchrotron Park’s #10YearChallenge 01/02/2019 Eurecat, a provider of innovative technologies 25/01/2019 ALBA Synchrotron’s expertise involved in the design of two scientific facilities 18/01/2019 Stradivarius will launch perfumes 11/01/2019 Graphene-based implant developed by IMB and ICN2 on UAB campus records brain activity 03/01/2019 CREAF: 30 years in environmental sciences
5 6 7 8 9 10 11 12 13 14 15